Skip to main content
Equibles
TVTX logo

TVTX · Travere Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track TVTX — free

Use TVTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TVTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$50.85 -0.04 (-0.07%) At close · Oct 28 Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$4.73B
Shares
94.26M
Volume · Oct 28 1.57M Avg daily vol (3M) 1.78M

Travere Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Travere Therapeutics, Inc. (TVTX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-02
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-08-11
Travere Therapeutics, Inc. (TVTX) August 11, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Travere Therapeutics, Inc. (TVTX) Q2 2026 Earnings Call Transcript
Confident tone Filspari FSGS launch Filspari in IgA Nephropathy Q2 commercial / financial performance
Revenue
$169.58M
▲ 48.2% YoY
Diluted EPS
$-0.37
Gross margin
98.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Travere Therapeutics, Inc. (TVTX) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Travere Therapeutics, Inc. (TVTX) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-13
Travere Therapeutics, Inc. (TVTX) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-04
Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript
Confident tone FSGS approval and launch IgA nephropathy commercial performance FSGS patient eligibility and sequencing
Revenue
$127.20M
▲ 55.6% YoY
Diluted EPS
$-0.40
Gross margin
98.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-13
Travere Therapeutics, Inc. (TVTX) April 13, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-19
Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript
Confident tone FILSPARI commercial performance in IgA nephropathy Cross-indication synergy between IgAN and FSGS FSGS regulatory path and PDUFA
Revenue
$129.69M*
▲ 73.4% YoY
Gross margin
98.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript
Confident tone FILSPARI commercial growth in IgA nephropathy FSGS approval opportunity and launch readiness REMS modification and potential full removal
Revenue
$164.86M
▲ 162.1% YoY
Diluted EPS
$0.28
Gross margin
99.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript
Confident tone FILSPARI IgAN commercial performance FSGS sNDA and regulatory progress Clinical evidence and SPARTAN/PROTECT data
Revenue
$114.45M
▲ 111.5% YoY
Diluted EPS
$-0.14
Gross margin
98.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript
Confident tone FILSPARI in IgA Nephropathy KDIGO Guidelines and Treatment Practice Changes FILSPARI sNDA for FSGS
Revenue
$81.73M
▲ 97.5% YoY
Diluted EPS
$-0.47
Gross margin
94.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript
Confident tone FILSPARI commercial momentum in IgAN Pre-commercial readiness for potential FSGS launch FSGS expansion opportunity
Revenue
$74.79M*
▲ 66% YoY
Gross margin
96.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Travere Therapeutics, Inc. (TVTX) Q3 2024 Earnings Call Transcript
Confident tone REMS liver monitoring modification FILSPARI IgAN launch KDIGO guidelines / treatment threshold
Revenue
$62.90M
▲ 69.6% YoY
Diluted EPS
$-0.70
▼ 135.5% YoY
Gross margin
97.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Travere Therapeutics, Inc. (TVTX) Q2 2024 Earnings Call Transcript
Confident tone FILSPARI launch performance and demand growth sNDA review and anticipated full approval FSGS and PARASOL regulatory path
Revenue
$54.12M
▲ 68.1% YoY
Diluted EPS
$-0.91
Gross margin
96.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript
Confident tone FILSPARI U.S. commercial launch IgAN treatment paradigm shift Pegtibatinase / HARMONY Phase 3 program
Revenue
$41.37M
▲ 33.9% YoY
Diluted EPS
$-1.76
Gross margin
96.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript
Confident tone FILSPARI launch momentum in IgAN Long-term kidney function data (PROTECT 2-year) sNDA submission for full approval
Revenue
$45.06M
▲ 53.6% YoY
Diluted EPS
$-1.18
Gross margin
89.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Travere Therapeutics, Inc. (TVTX) Q3 2023 Earnings Call Transcript
Revenue
$37.09M
▲ 32.1% YoY
Diluted EPS
$1.97
Gross margin
96.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Travere Therapeutics, Inc. (TVTX) Q2 2023 Earnings Call Transcript
Revenue
$32.20M
▲ 12.4% YoY
Diluted EPS
$-1.13
Gross margin
95.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Travere Therapeutics, Inc. (TVTX) Q1 2023 Earnings Call Transcript
Revenue
$30.89M
▲ 31.9% YoY
Diluted EPS
$-1.27
Gross margin
86.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Travere Therapeutics, Inc. (TVTX) Q4 2022 Earnings Call Transcript
Revenue
$29.34M
Diluted EPS
$-1.03
Gross margin
103.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Travere Therapeutics, Inc. (TVTX) Q3 2022 Earnings Call Transcript
Revenue
$28.07M
▼ 58.8% YoY
Diluted EPS
$-1.09
Gross margin
96.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Travere Therapeutics, Inc. (TVTX) Q2 2022 Earnings Call Transcript
Revenue
$28.63M
▼ 47.6% YoY
Diluted EPS
$-1.05
Gross margin
92.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Travere Therapeutics, Inc. (TVTX) Q1 2022 Earnings Call Transcript
Revenue
$23.41M
▼ 50.6% YoY
Diluted EPS
$-1.20
Gross margin
90.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Travere Therapeutics, Inc. (TVTX) Q4 2021 Earnings Call Transcript
Revenue
−$38.41M*
▼ 175.3% YoY
Gross margin
97.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Travere Therapeutics, Inc. (TVTX) Q3 2021 Earnings Call Transcript
Revenue
$68.22M
▲ 33.4% YoY
Diluted EPS
$-0.59
Gross margin
97.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Travere Therapeutics, Inc. (TVTX) Q2 2021 Earnings Call Transcript
Revenue
$54.62M
▲ 12.8% YoY
Diluted EPS
$-0.64
Gross margin
97.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Travere Therapeutics, Inc. (TVTX) Q1 2021 Earnings Call Transcript
Revenue
$47.41M
▼ 0.8% YoY
Diluted EPS
$-0.96
▼ 4900% YoY
Gross margin
96.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-10
Travere Therapeutics, Inc. (TVTX) Q4 2020 Earnings Call Transcript
Revenue
$50.98M
▲ 9.2% YoY
Gross margin
95.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Travere Therapeutics, Inc. (TVTX) Q3 2020 Earnings Call Transcript
Revenue
$51.14M
▲ 15.2% YoY
Diluted EPS
$-0.44
Gross margin
97.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Travere Therapeutics, Inc. (TVTX) Q2 2020 Earnings Call Transcript
Revenue
$48.43M
▲ 8.3% YoY
Diluted EPS
$-0.58
Gross margin
96.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Travere Therapeutics, Inc. (TVTX) Q1 2020 Earnings Call Transcript
Revenue
$47.77M
▲ 20.7% YoY
Diluted EPS
$0.02
Gross margin
97.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–32 of 32 webcasts
Key facts CIK 1438533 CUSIP 89422G107 13F (30d) 53 filings 50 filers Visit website Investor relations